Exelixis, Inc. $EXEL Stock Position Raised by Milestone Asset Management LLC

Posted by Brenda Bartman on Oct 16th, 2026

Milestone Asset Management LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 581.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 200,127 shares of the biotechnology company’s stock after purchasing an additional 170,738 shares during the period. Exelixis comprises about 1.9% of Milestone Asset Management LLC’s investment portfolio, making the stock its 8th biggest position. Milestone Asset Management LLC owned 0.08% of Exelixis worth $11,689,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. Private Client Services LLC increased its holdings in shares of Exelixis by 0.7% during the third quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock worth $1,667,000 after buying an additional 209 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Exelixis by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock worth $2,549,000 after acquiring an additional 281 shares in the last quarter. Brindle & Bay Financial Advisors LLC boosted its holdings in shares of Exelixis by 8.0% in the 3rd quarter. Brindle & Bay Financial Advisors LLC now owns 4,105 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 305 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its position in Exelixis by 3.8% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock worth $389,000 after acquiring an additional 333 shares during the last quarter. Finally, Mather Group LLC. grew its position in Exelixis by 124.6% during the 3rd quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 420 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In other news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the transaction, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on EXEL shares. Zacks Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Friday, September 11th. HC Wainwright reissued a “buy” rating and set a $56.00 price objective on shares of Exelixis in a report on Thursday, July 2nd. Stifel Nicolaus raised their price objective on shares of Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $50.79.

View Our Latest Research Report on EXEL

Exelixis Stock Performance

NASDAQ EXEL opened at $62.83 on Friday. The stock has a market capitalization of $15.57 billion, a P/E ratio of 19.76, a price-to-earnings-growth ratio of 1.71 and a beta of 0.47. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $63.31. The stock has a fifty day moving average of $56.73 and a 200-day moving average of $52.81.

Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 earnings per share. Equities research analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Exelixis Profile

(Free Report)

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California.